-+ 0.00%
-+ 0.00%
-+ 0.00%

AEON Biopharma Presents ABP-450 Development Strategy as Botox Biosimilar

PUBT·10/23/2026 20:16:34
Listen to the news
AEON Biopharma Presents ABP-450 Development Strategy as Botox Biosimilar
  • AEON Biopharma is advancing ABP-450 through the FDA's biosimilar pathway, targeting all 12 BOTOX therapeutic indications in a $3.5 billion US market.
  • An investigational new drug submission for the CMAP pharmacodynamic study is planned for Q4 2026; study initiation is expected in Q1 2027.
  • FDA feedback opened the possibility of incorporating prior ABP-450 versus BOTOX studies into the biosimilar evidence package, subject to appropriate scientific bridging.
  • ABP-450 is expected to price below BOTOX, potentially improving provider economics while giving payers a lower-cost alternative.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.